Naquotinib
Cat. No.：YN340305
| 产品名称: | Naquotinib |
| CAS No.: | 1448232-80-1 |
| Chemical Name: | 6-ethyl-3-[[4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[[(3R)-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl]oxy]-2-pyrazinecarboxamide |
| Synonyms: | ASP8273 |
| 分子量: | 562.7 |
| 分子式: | C30H42N8O3 |
| SMILES: | CN1CCN(C2CCN(C3=CC=C(NC4=NC(O[C@H]5CN(C(C=C)=O)CC5)=C(CC)N=C4C(N)=O)C=C3)CC2)CC1 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Naquotinib (ASP8273) 是有口服活性，不可逆的EGFR突变体抑制剂；对EGFR突变体和EGFR的IC50值分别为8-33和230 nM。 |
| IC50和靶点: | [{name:"EGFR:230 nM (IC50)'}, 'EGFRT790M', 'EGFRL858R/T790M', 'EGFRL858R', 'EGFRExon 19 deletion/T790M'] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Hirano, T., Yasuda, H., Hamamoto, J., et al.Pharmacological and structural characterizations of naquotinib, a novel third-generation EGFR tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancerMol. Cancer Ther.17(4),740-750(2018)
Ninomiya, K., Ohashi, K., Makimoto, G., et al.MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinibSci. Rep.8(1),1955(2018)
